Biotech

Biotech

Illumina earnings points to worrying signs for consumer genetics industry

By Damian Garde

Biotech

Christi Shaw, inspired by her sister’s cancer, named CEO of Kite Pharma, Gilead’s anti-cancer unit

By Matthew Herper

The Readout LOUD

Listen: A whirlwind week in Washington, Sean Parker’s mansion, & remembering a resonant voice in biotech

By Damian Garde and Rebecca Robbins

Biotech

Mass. Gov. Charlie Baker’s plan to curb drug prices strains his relationship with biotechs

By Priyanka Dayal McCluskey — Boston Globe

Biotech

23andMe’s chief scientific officer, a star in drug development, is leaving role

By Kate Sheridan

Biotech

Johnson & Johnson partners with Celsius Therapeutics in large-scale test of single-cell sequencing

By Kate Sheridan

Biotech

Takeda, already a giant in Mass. biopharma, plans a bigger footprint

By Jonathan Saltzman — Boston Globe

Biotech

Experimental gene therapy for hemophilia, developed by Pfizer and Sangamo, shows early promise

By Damian Garde

Biotech

FDA approves new multiple myeloma drug despite toxicity concerns

By Adam Feuerstein

Biotech

Stem-cell biotech seeing strong growth

By Jonathan Saltzman — Boston Globe

Business

Amarin raises sales guidance for heart drug Vascepa, hires more sales reps for larger marketing push

By Adam Feuerstein

Biotech

The race for a better Duchenne treatment: Adam and Matt talk Pfizer, Sarepta, and gene therapy

By Adam Feuerstein and Matthew Herper

Biotech

The biotech scorecard for the third quarter: 12 stock-moving events to watch

By Adam Feuerstein

Biotech

Pfizer, with early but hopeful results, leaps into the race for a Duchenne gene therapy

By Matthew Herper

Biotech

Sleek and sometimes secretive, Draper is carving out a role in drug development

By Kate Sheridan

The Readout LOUD

Listen: The future of AbbVieGan, the dogma of amyloid, & some questionable biotech marketing

By Damian Garde and Adam Feuerstein

Biotech

Bruised by Wall Street, Ovid Therapeutics may be one step closer to vindication with rare disease drug

By Damian Garde

Biotech

The wait just got longer to see Biogen’s data on its failed Alzheimer’s treatment

By Damian Garde

Biotech

How Brent Saunders’ Allergan experiment failed

By Matthew Herper

Biotech

A stem cell company is touting a stroke survivor’s recovery. Its media blitz offers investors a mirage

By Adam Feuerstein

Biotech

Patent office reopens major CRISPR battle between Broad Institute and Univ. of California

By Sharon Begley

Special Report

The maddening saga of how an Alzheimer’s ‘cabal’ thwarted progress toward a cure for decades

By Sharon Begley

Business

It’s Pioneer Institute vs. ICER: Drug-pricing watchdog comes under fire for a ‘one-size-fits-all’ approach

By Jonathan Saltzman — Boston Globe

In the Lab

Why are elite athletes different than the rest of us? Take a look at their microbes

By Elizabeth Cooney

Biotech

Bristol’s merger headaches may be contagious

By Matthew Herper

GSK took a leap of faith on PARP inhibitors in cancer. It may pay off

Weeks after Kymera signed $70m deal with Vertex, the biotech’s CEO is out

In a small study, a cancer vaccine assist beats immunotherapy drugs alone

With $5 billion Galapagos deal, CEO Daniel O’Day starts putting his stamp on Gilead

Illumina earnings points to worrying signs for consumer genetics industry

Christi Shaw, inspired by her sister’s cancer, named CEO of Kite Pharma, Gilead’s anti-cancer unit

Listen: A whirlwind week in Washington, Sean Parker’s mansion, & remembering a resonant voice in biotech

Mass. Gov. Charlie Baker’s plan to curb drug prices strains his relationship with biotechs

23andMe’s chief scientific officer, a star in drug development, is leaving role

Johnson & Johnson partners with Celsius Therapeutics in large-scale test of single-cell sequencing

Takeda, already a giant in Mass. biopharma, plans a bigger footprint

Experimental gene therapy for hemophilia, developed by Pfizer and Sangamo, shows early promise

FDA approves new multiple myeloma drug despite toxicity concerns

Stem-cell biotech seeing strong growth

Amarin raises sales guidance for heart drug Vascepa, hires more sales reps for larger marketing push

The race for a better Duchenne treatment: Adam and Matt talk Pfizer, Sarepta, and gene therapy

The biotech scorecard for the third quarter: 12 stock-moving events to watch

Pfizer, with early but hopeful results, leaps into the race for a Duchenne gene therapy

Sleek and sometimes secretive, Draper is carving out a role in drug development

Listen: The future of AbbVieGan, the dogma of amyloid, & some questionable biotech marketing

Bruised by Wall Street, Ovid Therapeutics may be one step closer to vindication with rare disease drug

The wait just got longer to see Biogen’s data on its failed Alzheimer’s treatment

How Brent Saunders’ Allergan experiment failed

A stem cell company is touting a stroke survivor’s recovery. Its media blitz offers investors a mirage

Patent office reopens major CRISPR battle between Broad Institute and Univ. of California

The maddening saga of how an Alzheimer’s ‘cabal’ thwarted progress toward a cure for decades

It’s Pioneer Institute vs. ICER: Drug-pricing watchdog comes under fire for a ‘one-size-fits-all’ approach

Why are elite athletes different than the rest of us? Take a look at their microbes

Bristol’s merger headaches may be contagious

Biotech

Sign up for our Daily Recap newsletter